Literature DB >> 2448783

Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.

H A Stafford1, M L Tykocinski, D M Lublin, V M Holers, W F Rosse, J P Atkinson, M E Medof.   

Abstract

In paroxysmal nocturnal hemoglobinuria (PNH), an acquired hemolytic anemia, deficiency of decay accelerating factor (DAF) renders blood cells susceptible to increased deposition of autologous complement activation fragments (C3b) and complemented-mediated injury. To investigate the mechanism of the DAF defect, DNA and mRNA from normal and PNH leukocytes were compared in blot hybridization assays by using DAF cDNA and oligonucleotide probes. Southern analyses of DNA from normal cells revealed a single gene spanning approximately equal to 35 kilobases of DNA. Six HindIII banding patterns were distinguishable among normal individuals. In family studies, the patterns segregated as three homozygous and three heterozygous genotypes deriving from three haplotypes: A, B, and C with frequencies of 0.47, 0.36, and 0.17, respectively. Oligonucleotide mapping localized the polymorphic HindIII sites to two noncoding regions in the vicinity of exons encoding (i) the protein oligosaccharide-rich domain and (ii) the mRNA 3'-untranslated region. Analyses of DNA from DAF-negative leukocytes of eight PNH patients demonstrated restriction fragment profiles identical to those of normal individuals for all enzymes studied. Three patients had the BC (normals = 3/32), three patients had the AA (normals = 6/32), and two patients had the AC (normals = 8/32) HindIII genotype. Of the three PNH patients exhibiting the BC genotype, family studies of two demonstrated the expected inheritance patterns, and RNA gel blot analyses of two showed mRNA transcripts indistinguishable from those in normal cells. The absence of DAF gene or mRNA alterations in affected PNH cells that lack other glycolipid-anchored proteins as well as DAF argues that the lesion underlying PNH cells resides in the glycolipid-anchor pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448783      PMCID: PMC279660          DOI: 10.1073/pnas.85.3.880

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Eukaryotic protein modification and membrane attachment via phosphatidylinositol.

Authors:  G A Cross
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

Review 2.  DNA restriction fragment length polymorphisms and heterozygosity in the human genome.

Authors:  D N Cooper; J Schmidtke
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

3.  Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system.

Authors:  A Nicholson-Weller; J P March; C E Rosen; D B Spicer; K F Austen
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

4.  Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.

Authors:  G M Hänsch; S Schönermark; D Roelcke
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

5.  Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  M E Medof; A Gottlieb; T Kinoshita; S Hall; R Silber; V Nussenzweig; W F Rosse
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

6.  Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.

Authors:  M E Medof; D M Lublin; V M Holers; D J Ayers; R R Getty; J F Leykam; J P Atkinson; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

Review 8.  Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.

Authors:  T Kinoshita; M E Medof; R Silber; V Nussenzweig
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

9.  Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.

Authors:  L S Zalman; L M Wood; M M Frank; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

10.  Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.

Authors:  M E Medof; E I Walter; J L Rutgers; D M Knowles; V Nussenzweig
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Farming for spare body parts: silk purse or sow's ear.

Authors:  J P Atkinson
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

2.  Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.

Authors:  D M Lublin; E S Thompson; A M Green; C Levene; M J Telen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 3.  Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.

Authors:  C J Parker
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

Review 4.  [Paroxysmal nocturnal hemoglobinuria].

Authors:  P Blaas; S Weber; G M Hänsch; H H Peter
Journal:  Klin Wochenschr       Date:  1990-03-05

5.  Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.

Authors:  D J Carothers; S V Hazra; S W Andreson; M E Medof
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

Review 6.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype.

Authors:  C G Tate; M Uchikawa; M J Tanner; P A Judson; S F Parsons; G Mallinson; D J Anstee
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

8.  Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.

Authors:  M M Lederman; S F Purvis; E I Walter; J T Carey; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Differential expression of glycosylphosphatidylinositol-anchored proteins in a murine T cell hybridoma mutant producing limiting amounts of the glycolipid core. Implications for paroxysmal nocturnal hemoglobinuria.

Authors:  L J Thomas; M Urakaze; R DeGasperi; T Kamitani; E Sugiyama; H M Chang; C D Warren; E T Yeh
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

10.  Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.

Authors:  W D Ratnoff; J J Knez; G M Prince; H Okada; P J Lachmann; M E Medof
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.